Anti-Kickback Statute

Fulgent Genetics, Inc. Class Action Lawsuit: Robbins LLP Reminds Shareholders of Lead Plaintiff Deadline in Class Action Against Fulgent Genetics, Inc. (FLGT)

Retrieved on: 
Thursday, September 29, 2022

Fulgent provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patents in the U.S. and internationally.

Key Points: 
  • Fulgent provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patents in the U.S. and internationally.
  • If you would like more information about Fulgent Genetics Inc.'s misconduct, click here .
  • Next Steps: If you acquired shares of Fulgent Genetics, Inc. between March 22, 2019 and August 4, 2022, you have until November 21, 2022, to ask the court to appoint you lead plaintiff for the class.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Investor Alert: Fulgent Genetics, Inc. (FLGT) - Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Announces Class Action and Encourages Shareholders to Contact the Firm and Actively Participate

Retrieved on: 
Thursday, September 29, 2022

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

FULGENT GENETICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Fulgent Genetics, Inc. - FLGT

Retrieved on: 
Wednesday, September 28, 2022

This action is pending in the United States District Court for the Central District of California.

Key Points: 
  • This action is pending in the United States District Court for the Central District of California.
  • Fulgent investors should visit us at https://claimsfiler.com/cases/nasdaq-flgt/ or call toll-free (844) 367-9658.
  • Fulgent and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements.

FULGENT GENETICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Fulgent Genetics, Inc.

Retrieved on: 
Tuesday, September 27, 2022

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Central District of California against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of a class of all persons and entities who purchased the publicly traded securities of Fulgent securities between March 22, 2019 and August 4, 2022, both dates inclusive (the “Class Period”).

Key Points: 
  • All investors who purchased the shares of Fulgent Genetics, Inc. and incurred losses are advised to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774.
  • You may obtain additional information concerning the action or join the case on our website, www.whafh.com .
  • If you have incurred losses in Fulgent Genetics, Inc., you may, no later than November 21, 2022, request that the Court appoint you lead plaintiff of the proposed class.
  • Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fulgent Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – FLGT

Retrieved on: 
Tuesday, September 27, 2022

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fulgent Genetics, Inc. (Fulgent or the Company) (NASDAQ: FLGT) and certain of its officers.

Key Points: 
  • NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fulgent Genetics, Inc. (Fulgent or the Company) (NASDAQ: FLGT) and certain of its officers.
  • If you are a shareholder who purchased Fulgent securities during the Class Period, you have until November 21, 2022 to ask the Court to appoint you as Lead Plaintiff for the class.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulgent Genetics, Inc. (FLGT)

Retrieved on: 
Tuesday, September 27, 2022

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming November 21, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fulgent Genetics, Inc. (Fulgent or the Company) (NASDAQ: FLGT ) securities between March 22, 2019 and August 4, 2022, inclusive (the Class Period).

Key Points: 
  • Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming November 21, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fulgent Genetics, Inc. (Fulgent or the Company) (NASDAQ: FLGT ) securities between March 22, 2019 and August 4, 2022, inclusive (the Class Period).
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Fulgent securities during the Class Period, you may move the Court no later than November 21, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

FULGENT GENETICS, INC. (NASDAQ: FLGT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulgent Genetics, Inc. (NASDAQ: FLGT)

Retrieved on: 
Tuesday, September 27, 2022

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) between March 22, 2019 and August 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Fulgent, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.
  • If you purchased Fulgent securities, and/or would like to discuss your legal rights and options please visit Fulgent Genetics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Palantir, Fulgent, Yatsen, and Barclays and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, September 27, 2022

The Company has two operating segments, commercial and government,with the latter primarily serving agencies in the U.S. federal government and non-U.S. governments.

Key Points: 
  • The Company has two operating segments, commercial and government,with the latter primarily serving agencies in the U.S. federal government and non-U.S. governments.
  • On May 9, 2022, Palantir issued a press release announcing its Q1 financial results and guidance for Q2.
  • For more information on the Barclays class action go to: https://bespc.com/cases/BCS
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulgent Genetics, Inc. (FLGT)

Retrieved on: 
Monday, September 26, 2022

Investors suffering losses on their Fulgent investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Fulgent investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing that the SEC was conducting an investigation into certain Exchange Act reports for 2018 through the first quarter of 2020.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR NOTIFICATION: Kessler Topaz Meltzer & Check, LLP Announces Lead Plaintiff Deadline on November 21, 2022 in Securities Fraud Class Action Lawsuit Filed against Fulgent Genetics, Inc.

Retrieved on: 
Saturday, September 24, 2022

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Fulgent Genetics, Inc. (Fulgent) ( NASDAQ: FLGT ).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Fulgent Genetics, Inc. (Fulgent) ( NASDAQ: FLGT ).
  • Kessler Topaz Meltzer & Check, LLP encourages Fulgent investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.